Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells

Y. ZHANG1,‡, C. BAO2,‡, Q. MU3, J. CHEN4, J. WANG1, Y. MI5, A. J. SAYARI6, Y. CHEN1,*, M. GUO2,*

1Anhui medical university, School of Clinical medicine (174-hospital), Xiamen; 2Department of Thoracic And Cardiovascular Surgery, the 174th Hospital of the Chinese People’s Liberation Army, the Affiliated Chenggong Hospital of Xiamen University, Xiamen, China; 3Department of Neurosurgery, Hongqi Hospital of Mudanjiang Medical University, Heilongjiang, China; 4The pharmacy college of Xiamen University, Xiamen, China; 5Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China; 6University of Miami Miller School of Medicine, Miami, FL, USA

*Correspondence: chenyq707@163.com, baochuanen@yahoo.com
‡Contributed equally to this work.

Received August 6, 2015 / Accepted November 13, 2015

Cisplatin is regularly used in the treatment of lung cancer. However, its efficacy is limited because of drug resistance. In this study, we found that Akt expression and activity was increased in lung cancer cells with acquired cisplatin resistance (A549/DDP cells and H460/DDP cells) when compared to their parental cells. Inhibition of phosphatidylinositol 3-kinase (PI3K)/Akt kinase activity by its natural inhibitor, Wortmannin, could sensitize DDP-resistant cells to DDP and reverse DDP resistance. Combination treatment of Wortmannin with cisplatin is capable of increasing the mortality rate of both A549/DDP cells and H460/DDP cells. The present study also demonstrated that hyperactivation of PI3K/Akt pathway is closely associated with cisplatin resistance by regulating the Bax-mitochondria-mediated apoptosis pathway in human lung cancer. Inhibition of PI3K/Akt activity in A549/DDP cells and H460/DDP cells could reverse cisplatin resistance by enhancing the effect of cisplatin on Bax oligomerization and release of Cytochrome C, allowing activation of the caspase-mediated apoptosis pathway. In conclusion, cisplatin resistance of lung cancer can be reversed via the inhibition of the PI3K/Akt signaling pathway. Therefore, both PI3K and Akt may be potential targets for overcoming cisplatin resistance in lung cancer.

Key words: wortmannin, lung cancer, cisplatin resistance, apoptosis

Lung cancer is still one of the major causes of death from cancer worldwide. Among the two classes of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), NSCLC accounts for approximately 90% of all lung cancers[1]. Compared to small cell carcinoma of the lung, NSCLC is any type of epithelial lung cancer exhibiting less sensitivity to chemotherapy. Furthermore, reports have shown that platinum-based chemotherapy is effective in treating lung cancer [2]. Unfortunately, however, after a period of treatment, cisplatin-resistant lung cancer cells result in eventual chemotherapy failure [3].

To solve this vexing drug resistance problem, combination therapy has been the solution over the last two decades, owing to their synergistic effects seen in some trials[4-6]. Although drug resistance is a common phenomenon in chemotherapy, the puzzling mechanism involving complicated signaling pathways is not entirely clear. In order to avoid the effect of chemotherapeutics, tumor cells often elevate their expression level of several proteins, rendering themselves resistant to apoptosis.

The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is one of the vital links between extracellular stimuli and fundamental cellular processes, playing a vital role in tumor cell proliferation, apoptosis, and survival [7]. Accumulating evidence has further confirmed that aberrant activation of PI3K and Akt contributes to drug resistance in many types of cancer, including lung cancer[8-10]. As a member of lipid kinase family, PI3K has been extensively researched for its importance in various signaling pathways [11]. PI3K is a heterodimer composed of two subunits, including a regulatory
were induced as follows: cells were continuously exposed to serum, 100U/ml penicillin, and 100 mg/ml streptomycin. Development of cisplatin resistance in A549 and H460 cells were maintained in RPMI-1640 medium (37°C, 10% CO2) supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. Development of cisplatin resistance in A549 and H460 cells were induced as follows: cells were continuously exposed to escalating cisplatin concentrations ranging from 3nmol/L to 200 μmol/L, over a 3-month period. Resistant cells were named A549/DDP and H460/DDP. The chemoresistant ability of A549/DDP and H460/DDP cells was assessed by MTT assay. Both cisplatin-sensitive parental cells and cisplatin-resistant cells were treated with 5, 10, 20, 40, 80, 120, and 200 μmol/L cisplatin for 48 h, and the inhibition ratio was measured.

**Inhibition ratio assay.** The cells were seeded into 96-well plates at a starting density of 2×10^4 cells per well and cultured overnight. Then, various concentrations of drugs were added to the medium for 48 h. The in vitro cell viability effects of cisplatin, Wortmannin, alone, or in combination, were determined by MTT assay. For this assay, we tested two sequences: (a) serial concentrations of cisplatin alone, and (b) serial concentrations of cisplatin plus Wortmannin (2.5 nmol/L for A549/DDP, 5 nmol/L for H460/DDP).

**Apoptosis assay.** The treatment method of the cell strains in the apoptosis assay is similar to the previously mentioned cell viability assay. In the apoptosis assay, flow detection was measured via the FITC-annexin V/PI binding assay. Analysis was carried out based on flow cytometry (Becman ALTRA, USA), and the results were analyzed using WinMDI 2.9 software.

**Detection of caspases-3, caspases-8 and caspases-9 activity.** The activity of caspase-3, caspase-8 and caspase-9 were detected using the caspase activity kit (Bio excellence International Tech Co, Ltd). The caspase activity value was determined by detecting the absorbance at 490nm. Both A549/DDP and H460/DDP cells were collected and lysed in caspase assay buffer, and the supernatant was collected to detect activity.

**Western blotting analysis.** Following treatment for the cell viability assay, cells were washed twice with PBS and harvested in a chilled lysis buffer (10mm PBS buffer, containing 50mm KCl, 0.1mm PMSF, 0.5 mg/ml aprotinin, 0.5mM sodium-metavanadate, 1mM EDTA, pH 7.6). Following cell lysis, the total proteins were obtained by centrifugation, and supernatants were adjusted to equal amounts of protein for SDS-PAGE. Separate proteins were electroblotted from SDS-PAGE onto PVDF membranes, and then blocked overnight with 5% nonfat milk powder and 0.1% Tween 20 in PBS at 4°C. Afterwards, blots were exposed to a primary antibody for 1 h at room temperature. After extensive washing with blocking solution, blots were exposed to the appropriate secondary antibody with HRP and detected by an ECL kit (Amersham Pharmacia Biotech).

**Statistical analysis.** Analysis of densitometry for Western blot was performed by using Image J. Data are presented as means ± standard deviation (SD). Cell viability assay and apoptosis experiments were performed at least twice with duplicates. For multiple comparisons of groups, ANOVA was used by origin 8.0. Statistical difference between groups was analyzed by unpaired two-tailed Students t-test, Value of p < 0.05 or p < 0.01 was considered as that there is a discrepancy or significant discrepancy between two groups.
Results

Establishment of cisplatin-resistant cells. As shown in Figure 1, the inhibition ratios of both parental and cisplatin-resistant cell strains were increased in a dose-dependent manner, with the parental lung cancer cells, A549 and H460, appearing more sensitive than their resistant variants, A549/DDP and H460/DDP. This suggests that both A549/DDP and H460/DDP acquired cisplatin-resistance after being continuously exposed to increasing levels of cisplatin for 3 months. The IC_{50} values for A549/DDP, H460/DDP were 70.7±3.5 μmol/L and 53.0±5.2 μmol/L, respectively, a statistically significant difference when compared to A549 and H460 (11.4±2.8 μmol/L and 8.8±1.5 μmol/L, p<0.01). The resistance index for A549/DDP and H460/DDP was 6.2 and 6.0, respectively.

PI3K/Akt pathway in cisplatin resistance. To further determine whether the PI3K/Akt pathway is responsible for cisplatin resistance in A549/DDP and H460/DDP, we analyzed the activation discrepancy of Akt and p-Akt between A549, H460 and cisplatin resistant strains, A549/DDP, H460/DDP.
cell lines. Figure 2 shows that a significantly higher level of phosphorylated Akt was detectable in A549/DDP and H460/DDP cells when compared to their parental cell lines, A549 and H460. When treated with serial concentrations of cisplatin, the cells strains acquired resistance still exhibited higher level of phosphorylated Akt in a dose-dependent manner when compared to their parental cell lines.

**Wortmannin’s effect on cisplatin-resistance in A549/DDP and H460/DDP cell lines.** We used a series of concentrations of Wortmannin to identify the minimum concentration required to return phosphorylation level of Akt to their normal range (Figure 3). After analysis, 2.5nmol/L and 5.0 nmol/L Wortmannin were considered the optimum concentrations for the A549/DDP and H460/DDP cell lines, respectively. The results showed that both A549/DDP and H460/DDP cell lines became more sensitive to cisplatin after Wortmannin treatment, and the mortality rate in the two cell lines dramatically increased (Figure 4). From the growth-inhibitory curves of the cell lines, we observed that the inhibition rate of A549/DDP cells in combination therapy group (90.5 %) was much higher than the monotherapy group (19.1 %) when both of them were treated with 40μmol/L cisplatin, and a similar phenomenon also occurred in H460/DDP cells (inhibition rate increased from 28.5 % to 96.3%). The IC\textsubscript{50} values of cisplatin for A549/DDP and H460/DDP cell lines were 9.4±2.1μmol/L and 9.0±1.3 μmol/L, respectively, in the Wortmannin combination therapy group, compared with 70.7±3.5 μmol/L and 53.0±5.2 μmol/L for A549/DDP and H460/DDP cell lines, respectively, in the monotherapy group (p < 0.01).

![Figure 3](image_url)

Figure 3. Cisplatin-stimulated Akt activity could be inhibited by Wortmannin. (A) A549 and A549/DDP cells were pre-treated with 40 μmol/L cisplatin, followed by the addition of 1,2.5,5,10 nmol/L Wortmannin, respectively, and cultivated for 16 h. Then, phosphorylation levels of Akt were visualized by Western Blot. (B) Parallel probes were also carried out on H460 and H460/DDP cells like A549 and A549/DDP cells. (C) The detailed phosphorylation differences between A549 and A549/DDP cells were showed by gray histogram. (D) The detailed phosphorylation differences between A549 and A549/DDP cells were showed by gray histogram. The relative intensity of each WB lane was analyzed by the image J 2x 2.1.4.7 soft. The proper concentrations for next experiments were selected by the standard phosphorylation level of Akt in cells have not statistically significant between parental and cisplatin resistant cell lines (p>0.05).
Wortmannin reverses the cisplatin resistance and enhances mortality rate on both A549/DDP and H460/DDP cells which were measured by MTT assay. All cells were exposed to 5, 10, 20 and 40 μmol/L cisplatin or together with Wortmannin (2.5 nmol/L for A549, 5 nmol/L for H460) respectively for 48 h, A549/DDP and H460/DDP cells which in the Wortmannin combination therapy group appear less cisplatin tolerance then the others in the monotherapy group. The experiments were repeated quintic. Columns, mean; bars, SD.

Wortmannin enhances apoptosis-promoting effect of cisplatin in A549/DDP and H460/DDP cell lines. Annexin V/PI-positive cells were markedly increased in the combination treatment group for both A549/DDP and H460/DDP cell lines when compared to monotherapy group (Figure 5). With a concentration of cisplatin of 40 μmol/L, the apoptotic rate of the combination treatment group (A549/DDP cell line, 79.2% and H460/DDP cell line, 75.7%) was significantly higher than the monotherapy group (A549/DDP cell line, 39.5% and H460/DDP cell line, 36.6%). In order to gain further insight into the molecular mechanism about how Wortmannin promotes the apoptosis effect of cisplatin, we examined caspase activity of apoptosis proteins caspase-3, caspase-8, and caspase-9. In the monotherapy group, the caspase-3, caspase-8, and caspase-9 enzyme activity in both A549/DDP and H460/DDP cells were significantly enhanced after exposure to Wortmannin (2.5 nmol/L for A549/DDP, 5 nmol/L for H460/DDP) (Figure 6).

Wortmannin's effect on cisplatin-resistance via PI3K/Akt pathway. The phosphorylation level of BAD and expression...
level of Bcl-2 and Bax proteins were detected by Western blot assay (Figure 7). In the monotherapy group, cisplatin caused apparent phosphorylation of Akt in A549/DDP cells, and increased phosphorylation of BAD. In contrast to the control group, Wortmannin prevented the phosphorylation level of Akt induced by cisplatin in the combined treatment group. Also in contrast to the control group, the expression level of Bax was significantly increased, while the expression level of Bcl-2 was decreased. Similar results were also obtained in H460/DDP cells.

Previous research has verified that a multimer of Bax is one of triggers in the mitochondrial apoptosis pathway [19, 20]. Increased expression of Bax often contributes to extracellular release of Cytochrome C from mitochondria to cytosol. After treatment with Wortmannin for 48 h, there was increased accumulation of Cytochrome C in the cytosol when compared...
to the control, in both A549/DDP and H460/DDP cell lines (Figure 8).

Discussion

Cisplatin-based chemotherapy is still the first line therapeutic treatment in lung cancer therapy. However, the emergence of resistance to chemotherapy has become a chief obstacle in effective cancer treatment. During the course of cisplatin therapy, there is a balance between survival and apoptotic signals, and a tilt towards the former directly contributes to cisplatin-resistance by these lung cancer cells. Akt was originally identified as the oncogene in the transforming retrovirus in 1977, and its role in regulating apoptosis has been identified[21]. Akt conveys pro-survival signals by phosphorylating and inactivating pro-apoptotic proteins, as well as downregulating the transcription of several pro-apoptotic genes[22-24]. Extensive studies in previous years focusing on the PI3K/Akt pathway have identified the crucial correlation between this pathway and chemoresistance in various human cancers [25, 26]. The occurrence of chemoresistance is often attributed to the abnormal activity of apoptosis-related proteins such as BAD, Bcl-XL and the caspase family. BAD could be activated by Akt, and their relationship suggests that the PI3K/Akt pathway could be a useful target in overcoming cisplatin resistance.

However, the PI3K/Akt pathway’s role in drug resistance and the underlying mechanism between these apoptosis-related proteins in human lung cancer remains unclear. To better understand the underlying mechanism of cisplatin resistance, we induced cisplatin resistance in human lung cancer cells. In our study, H460 cells were more sensitive to cisplatin-induced cytotoxicity than A549 cells, but similarly, hyperphosphorylation of Akt has been detected in both A549 and H460 cells when two cell lines acquire chemoresistance, indicating that cisplatin stimulates the PI3K/Akt pathway.

We found that in lower doses, Wortmannin, introduced as a specific inhibitor of PI3Ks, directly downregulated the phosphorylation level of Akt, significantly reversing cisplatin-resistance. Both A549/DDP and H460/DDP cell lines became more sensitive to cisplatin when compared to the monotherapy group which treated with cisplatin alone. Furthermore, a similar phenomenon was also observed in our apoptosis assay, suggesting that downregulation of hyperphosphorylation of Akt is an effective method of reversing the resistance of lung cancer cells to cisplatin, and re-sensitizing those cells to cisplatin-induced apoptosis. Accordingly, the similar research in earlier study Larisa L. Belyanskaya et al. [27] also gave our result a forceful support. Activated Akt could protected SCLC cells against cisplatin-induced apoptosis, whereas dominant negative Akt increased the cells sensitivity to cisplatin.

BAD is a pro-apoptotic protein of the Bcl-2 family involved in initiating apoptosis and other various components of chemotherapeutic resistance via the PI3K/Akt pathway[28]. We observed a similar trend, as stimulation of A549/DDP and H460/DDP cell lines with serial concentrations of cisplatin resulted in BAD activation via phosphorylation. It has been mentioned in several reports that the BAD-induced apoptosis pathway could be activated via Ser136 phosphorylation by Akt, and once activated, BAD will dissociate from the Bcl-2/Bcl-X complex, losing its pro-apoptotic function [29-31]. Then, the isolated Bcl-2 further prevents Bax from inserting into the mitochondrial membrane by disturbing Bid-induced Bax oligomerization [32, 33]. Bax oligomerization induces apoptosis by way of Cytochrome C release in the mitochondria [34, 35]. Once released, cytochrome c cooperates with apoptotic protease-activating factor-1 (Apaf-1) and induces caspase-9 activation, which is directly involved in the activation of executioner caspase-3[36]. Caspase-3 acts as a key executor in apoptosis and plays an important role in programmed cell death. Finally, activated caspase-3 causes DNA breakage, initiating cell apoptosis [37]. Because Bax oligomerization is an essential part of the Cytochrome C channel in the mitochondrial membrane[38, 39], the inhibition of Bax multimer formation plays a vital role in apoptotic resistance. In our study, we first proved that Wortmannin could increase the activation of caspase-3, caspase-8, and caspase-9 through the inhibition of the PI3K/Akt pathway, activating BAD and Cytochrome C release, confirming that cisplatin resistance is closely linked to caspase-dependent apoptosis and the PI3K/Akt pathway.

In conclusion, our data reveals that Wortmannin can induce both A549/DDP and H460/DDP cell lines to become more sensitive to cisplatin in vitro. We first found that its reversal mechanism of cisplatin-resistance: Wortmannin is able to devitalize the proapoptotic caspase adapter protein-BAD and launch the cascade reaction of caspase via PI3K/Akt pathway, then, the cascade reaction of caspase initiate the Cytochrome C release in the mitochondria which is the direct reason for reversion of cisplatin resistance. The present study demonstrates that PI3K/Akt plays a crucial role in the cisplatin resistance in human lung cancer cells. Cancer cells’ loss of PI3K activity facilitates apoptosis and recovers the sensitivity of cells to cisplatin. In summary, the results of the current study support PI3K/Akt as a valid therapeutic target and strongly suggest that PI3K/Akt inhibitors used in conjunction with conventional chemotherapy may be a potentially useful therapeutic strategy in treating lung cancer patients.

References


et al. Combination therapy with ruxolitinib - 8 - 6 - 4 - 2


[27] BELYANSKAYA LL, HOPKINS-DONALDSON S, KURTZ S, SIMOES-WUST AP,...


